- Report
- April 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,416GBP
- Report
- August 2024
- 149 Pages
Global
From €2645EUR$2,999USD£2,281GBP
- Report
- August 2022
Global
From €3969EUR$4,500USD£3,423GBP
- Report
- December 2019
- 356 Pages
Global
From €13224EUR$14,995USD£11,407GBP
- Report
- July 2018
- 765 Pages
Global
From €19402EUR$22,000USD£16,735GBP
Plegridy is a medication used to treat relapsing forms of multiple sclerosis (MS). It is a type of central nervous system (CNS) drug, which works by reducing the activity of the immune system and decreasing inflammation in the brain and spinal cord. Plegridy is administered as an injection under the skin, and is usually taken once every two weeks. It is approved for use in adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
The Plegridy market is a subset of the larger CNS drug market, which includes medications used to treat a variety of neurological conditions. These drugs are used to manage symptoms, slow the progression of the disease, and improve quality of life. The CNS drug market is highly competitive, with many companies offering a range of treatments.
Some companies in the Plegridy market include Biogen, Merck, Novartis, and Sanofi. Show Less Read more